Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2381 to 2390 of 2733 total matches.

In Brief: Anktiva for Bladder Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024  (Issue 1705)
) are also approved for the same indication.1 underwent transurethral resection of the tumor before ...
Nogapendekin alfa inbakicept-pmln (Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors. Such patients generally undergo bladder tumor resection, followed by intravesical BCG treatment, but treatment failure and cancer recurrence are common. The adenoviral vector-based intravesical gene therapy nadofaragene firadenovec-vncg (Adstiladrin)...
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e105-6   doi:10.58347/tml.2024.1705e |  Show IntroductionHide Introduction

Drugs of Choice for Cancer

   
Treatment Guidelines from The Medical Letter • Mar 01, 2003  (Issue 7)
. (ISSN 1541-2784) Vol. 1 (Issue 7) March 2003 Published by The Medical Letter, Inc. 1000 Main ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Treat Guidel Med Lett. 2003 Mar;1(7):41-52 |  Show IntroductionHide Introduction

Vasodilators For Congestive Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 1988  (Issue 758)
(WHW Inman and NSB Rawson, Lancet, 1:872, 1987). PRAZOSIN — A postsynaptic alpha-adrenergic-receptor ...
Vasodilators are widely used for treatment of congestive heart failure (CHF) that has not responded adequately to diuretics and digitalis. Vasodilator drugs redistribute blood volume in patients with heart failure, lowering pressure and reducing volume in the failing left ventricle, which leads to increased cardiac output, decreased pulmonary capillary wedge pressure, and improved exercise tolerance. Since the last Medical Letter review of this subject (Volume 26, page 115, 1984), some additional data have become available.
Med Lett Drugs Ther. 1988 Jan 29;30(758):13-4 |  Show IntroductionHide Introduction

Prevention of Pneumocystis Carinii Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Oct 07, 1988  (Issue 776)
with aerosolized pentamidine (30 or 150 mg twice monthly or 300 mg once monthly) for an average of 3 1 /2 months ...
Pneumocystis carinii pneumonia (PCP) is a common cause of death in patients with acquired immune deficiency syndrome (AIDS). PCP is the first serious opportunistic infection in more than 60% of patients with AIDS, and about 80% of AIDS patients develop PCP at least once (AE Glatt et al, N Engl J Med, 318:1439, June 2, 1988). Many studies using drugs to prevent PCP in patients with AIDS have recently been reported.
Med Lett Drugs Ther. 1988 Oct 7;30(776):94-5 |  Show IntroductionHide Introduction

Octreotide - A Synthetic Somatostatin

   
The Medical Letter on Drugs and Therapeutics • Jul 14, 1989  (Issue 796)
that resist degradation by serum peptidases. It has a half-life of about 1.5 hours and can be giv- en ...
Octreotide acetate (Sandostatin - Sandoz), a synthetic octapeptide that mimics the actions of somatostatin, was recently approved by the US Food and Drug Administration for symptomatic treatment of patients with metastatic carcinoid or VIPomas (vasoactive intestinal peptide-secreting tumors).
Med Lett Drugs Ther. 1989 Jul 14;31(796):66-8 |  Show IntroductionHide Introduction

Olsalazine

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 1990  (Issue 831)
) similar to sulfasalazine (1 gram bid) in preventing relapse of ulcerative colitis in 164 patients treated ...
Olsalazine sodium (Dipentum - Pharmacia), a dimer (two molecules linked by an azo bond) of 5-aminosalicylic acid, was recently approved by the US Food and Drug Administration for oral use to maintain remission of ulcerative colitis in adult patients who cannot tolerate sulfasalazine (Azulfidine; and others).
Med Lett Drugs Ther. 1990 Nov 16;32(831):105-6 |  Show IntroductionHide Introduction

Mifepristone (RU 486)

   
The Medical Letter on Drugs and Therapeutics • Dec 14, 1990  (Issue 833)
. About 1% of patients have required curettage, and a few have had transfusions. ADVERSE EFFECTS — Except ...
Recent articles in the press have suggested that mifepristone (RU 486 - Roussel Uclaf) can effectively and safely induce an abortion. The drug is currently available only in France and China, but the manufacturer has also applied for a license in the United Kingdom. Mifepristone has been used on an investigational basis in the USA as an abortifacient and for treatment of Cushing's disease and breast cancer, but no manufacturer has applied to the US Food and Drug Administration for approval to market the drug in this country.
Med Lett Drugs Ther. 1990 Dec 14;32(833):112-4 |  Show IntroductionHide Introduction

Safety of Terfenadine and Astemizole

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 1992  (Issue 863)
in the liver. Once bound to H 1 -receptors, it dissociates very slowly, with a serum elimination half-life ...
Terfenadine (Seldane - Marion Merrell Dow) and astemizole (Hismanal - Janssen) are nonsedating antihistamines widely used to treat symptoms of allergic rhinitis (Medical Letter, 27:65, 1985; 31:43, 1989). Both are available without a prescription in Canada, and the US Food and Drug Administration is apparently considering terfenadine for over-the-counter availability in the USA.
Med Lett Drugs Ther. 1992 Feb 7;34(863):9-10 |  Show IntroductionHide Introduction

Nicotine Patches

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 1992  (Issue 868)
, or burning under the patch in 25% to 50% of patients (T Abelin et al, Lancet, 1:7, 1989; Transdermal ...
Three nicotine-releasing adhesive patches for the skin (Habitrol - Ciba-Geigy; Nicoderm - Marion Merrell Dow; and PROSTEP - Lederle) have been approved by the US Food and Drug Administration to aid withdrawal from smoking. Nicotrol (Parke-Davis) may also be approved soon. All the manufacturers recommend using the patches in conjunction with a behavioral modification program.
Med Lett Drugs Ther. 1992 Apr 17;34(868):37-8 |  Show IntroductionHide Introduction

Gabapentin - A New Anticonvulsant

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 1994  (Issue 921)
seizures (UK Gabapentin Study Group, Lancet, 335:1114, 1990; J Bruni et al, Neurology, 41 suppl 1:330 ...
Gabapentin (Neurontin - Parke-Davis), a cyclohexane acetic acid derivative, has been approved by the US Food and Drug Administration for use in addition to other antiepileptic drugs in patients with partial (focal) seizures with or without secondary generalization. Since this diagnostic category includes the largest number of patients with intractable epilepsy, new drugs with antiepileptic activity are generally tried first for this indication.
Med Lett Drugs Ther. 1994 Apr 29;36(921):39-40 |  Show IntroductionHide Introduction